{"page_content": "Appendix\n71  |  ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021\nIntroduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen\nSASB TOPIC ACCOUNTING METRICUNIT OF\nMEASURECODE REPORTING\nNumber of FDA enforcement actions taken in response to \nviolations of current Good Manufacturing Practices (cGMP), \nby typeNumber HC-BP-250a .5 Amgen discloses material legal and regulatory issues in its \nannual 10-K and quarterly 10-Qs  .\nCounterfeit DrugsDescription of methods and technologies used to maintain \ntraceability of products throughout the supply chain and \nprevent counterfeitingn/a HC-BP-260a .1 Pertinent reporting can be found in the Counterfeit Drug \nStatement on our website  .\nDiscussion of process for alerting customers and business \npartners of potential or known risks associated with \ncounterfeit productsn/a HC-BP-260a .2 Pertinent reporting can be found in the Counterfeit Drug \nStatement on our website  .\nNumber of actions that led to raids, seizure,  \narrests, and/or filing of criminal charges related  \nto counterfeit productsNumber HC-BP-260a .3 Amgen discloses material legal and regulatory issues in its \nannual 10-K and quarterly 10-Qs  .\nEthical MarketingTotal amount of monetary losses as a result of legal \nproceedings associated with false marketing claimsReporting currency HC-BP-270a .1 Amgen discloses material legal and regulatory issues in its \nannual 10-K and quarterly 10-Qs  .\nDescription of code of ethics governing promotion of \noff-label use of productsn/a HC-BP-270a .2 Our policy on Communications with Members of the \nHealthcare Community and the Amgen Code of Conduct \nprohibit off-label promotion and staff members are trained \non these requirements annually as described on the Staff \nCode Conduct section of our website  .APPENDIX", "metadata": {"source": "NASDAQ_AMGN_2021.pdf", "page": 70, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}